Source: Google NewsPublished on 2022-08-03
Related Articles:
- NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement - BioSpace February 23, 2021 NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement BioSpace
- Monthly Research Review – February 2021 February 28, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2021. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news…
- NeuroOne Medical Technologies (OTCMKTS:NMTC) and Acutus Medical (NASDAQ:AFIB) Head to Head Survey - Defense World July 11, 2022 NeuroOne Medical Technologies (OTCMKTS:NMTC) and Acutus Medical (NASDAQ:AFIB) Head to Head Survey Defense World
- NeuroOne Medical Technologies Corporation: Announces Fiscal Third Quarter 2019 Financial Results and Provides a Corporate Update - Yahoo Finance August 14, 2019 NeuroOne Medical Technologies Corporation: Announces Fiscal Third Quarter 2019 Financial Results and Provides a Corporate Update Yahoo FinanceMINNETONKA, MN / ACCESSWIRE / August 14, 2019 / NeuroOne Medical Technologies Corporation (NMTC), a medical device company focused on the ...
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- NeuroOne Featured on The Medical Alley Podcast: "A Conversation with Dave Rosa, President and CEO, NeuroOne" - Yahoo Finance December 20, 2021 NeuroOne Featured on The Medical Alley Podcast: "A Conversation with Dave Rosa, President and CEO, NeuroOne" Yahoo Finance
- Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s February 19, 2020 Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us…
- Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s February 19, 2020 Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us…
- Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s February 19, 2020 Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us…
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- NeuroOne Medical Technologies : ® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders - Form 8-K - Marketscreener.com June 2, 2022 NeuroOne Medical Technologies : ® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders - Form 8-K Marketscreener.com
- Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review. - StreetInsider.com May 13, 2021 Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review. StreetInsider.com
- NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11 - Marketscreener.com August 4, 2022 NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11 Marketscreener.com
- NeuroOne Announces Strategic Partnership with RBC Medical Innovations for Ablation Program - Yahoo Finance August 23, 2021 NeuroOne Announces Strategic Partnership with RBC Medical Innovations for Ablation Program Yahoo Finance
- NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode - BioSpace July 12, 2022 NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode BioSpace
- Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing - Benzinga May 11, 2021 Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing Benzinga
- Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing - Yahoo Finance May 11, 2021 Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing Yahoo Finance
- Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB - Business Wire May 17, 2021 Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB Business Wire
- Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB - BioSpace May 17, 2021 Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB BioSpace
- Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration - Cambridge Independent August 11, 2021 Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration Cambridge Independent
- NeuroOne(TM) Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode - Yahoo Finance September 23, 2019 NeuroOne(TM) Medical Technologies Corporation Announces First Sale of sEEG Depth Electrode Yahoo FinanceCompany's sEEG Electrode will be used for non-human research purposes by the Cleveland Clinic Foundation. MINNETONKA, MN / ACCESSWIRE ...